Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.

6. november 2026 opdateret af: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

The study is being conducted to evaluate the efficacy, and safety of SHR-A2009 combined with other anti-tumor therapies for perioperative treatment of resectable non-small cell lung cancer in adults.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

660

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Guangdong
      • Guangzhou, Guangdong, Kina, 510080
        • Guangdong Provincial People's Hospital
        • Ledende efterforsker:
          • Yilong Wu

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 70 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. voluntarily participate in this clinical study, understand the research procedure and be able to sign the informed consent in writing ;
  2. At the time of signing the informed consent form, the age is 18-70 years old ( including both ends ), both men and women can.
  3. The ECOG score was 0 or 1.
  4. Pathologically confirmed NSCLC, assessed as resectable or previously resected (R0).
  5. Adequate bone marrow and organ function.

Exclusion Criteria:

  1. Participants who received systemic immunostimulatory therapy within 4 weeks prior to the first dose.
  2. Participants who received systemic immunosuppressive therapy within 2 weeks before the first dose.
  3. Participants with active, known or suspected autoimmune diseases.
  4. Other malignant tumors within 5 years before screening.
  5. Participants with a history of interstitial pneumonia or cannot exclude interstitial pneumonia; or there are other moderate to severe lung diseases that may affect respiratory function. Or received previous pneumonectomy surgery.
  6. Participants with severe cardiovascular and cerebrovascular diseases.
  7. There were clinically significant bleeding symptoms or obvious bleeding tendency within 1 month before the first administration.
  8. Arterial and venous thrombosis events occurred within 3 months before the first administration.
  9. HIV test positive.
  10. Participants with active hepatitis B or C.

1.Evidence of active tuberculosis infection within 1 year before the first administration.

12.Severe infection occurred within 4 weeks before the first administration. 13.History of severe allergic reactions to other monoclonal antibody / fusion protein drugs.

14. Allergy to any component of the treatment regimen. 15.Participants were known to have a history of psychotropic drug abuse, alcohol abuse or drug abuse.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: group A1-1adebrelimab + SHR-A2009

adebrelimab + SHR-A2009

adebrelimab + SHR-A2009 (longer-interval regimen arm)

adebrelimab + SHR-A2009 (shorter-interval regimen arm)

Aktiv komparator: group A1-2 paclitaxel or pemetrexed combined with carboplatin +adebrelimab

paclitaxel or pemetrexed combined with carboplatin +adebrelimab

Eksperimentel: group1 A2-1adebrelimab + SHR-A2009 (longer-interval regimen arm)

adebrelimab + SHR-A2009

adebrelimab + SHR-A2009 (longer-interval regimen arm)

adebrelimab + SHR-A2009 (shorter-interval regimen arm)

Eksperimentel: group2 A2-2adebrelimab + SHR-A2009 (shorter-interval regimen arm)

adebrelimab + SHR-A2009

adebrelimab + SHR-A2009 (longer-interval regimen arm)

adebrelimab + SHR-A2009 (shorter-interval regimen arm)

Aktiv komparator: group A2-3 adebrelimab

adebrelimab

Eksperimentel: group1 A3-1 adebeliizumab + SHR-A2009 (longer-interval regimen arm)

adebeliizumab + SHR-A2009 (longer-interval regimen arm)

adebeliizumab + SHR-A2009 (shorter-interval regimen arm)

Eksperimentel: group2 A3-2 adebeliizumab + SHR-A2009 (shorter-interval regimen arm)

adebeliizumab + SHR-A2009 (longer-interval regimen arm)

adebeliizumab + SHR-A2009 (shorter-interval regimen arm)

Aktiv komparator: group A3-3 adebeliizumab + platinum-containing double chemotherapy

adebeliizumab + platinum-containing double chemotherapy

Eksperimentel: group B1-1 almonertinib combined with SHR-A2009 (longer-interval regimen arm)

almonertinib combined with SHR-A2009 (longer-interval regimen arm)

almonertinib combined with SHR-A2009 (shorter-interval regimen arm)

Eksperimentel: group B1-2 almonertinib combined with SHR-A2009 (shorter-interval regimen arm)

almonertinib combined with SHR-A2009 (longer-interval regimen arm)

almonertinib combined with SHR-A2009 (shorter-interval regimen arm)

Aktiv komparator: group B1-3 almonertinib

almonertinib

Eksperimentel: group B2-1 SHR-A2009 combined with almonertinib

SHR-A2009 combined with almonertinib

Aktiv komparator: group B2-2 almonertinib monotherapy

almonertinib monotherapy

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Part A1 : pCR rate;
Tidsramme: about 24 months
about 24 months
Part A2 : 2-year DFS rate;
Tidsramme: about 24 months
about 24 months
Part A3 : pCR rate and 18-month EFS rate;
Tidsramme: about 18 months
about 18 months
Part B1 : 2-year DFS rate.
Tidsramme: about 24 months
about 24 months
Part B2 : MPR rate.
Tidsramme: about 24 months
about 24 months

Sekundære resultatmål

Resultatmål
Tidsramme
The incidence and grade of adverse events;
Tidsramme: about 48 months
about 48 months
surgical complications;
Tidsramme: about 24 months
about 24 months
EFS
Tidsramme: about 24 months ;
about 24 months ;
ORR;
Tidsramme: about 24 months
about 24 months
DFS and DFS rates;
Tidsramme: about 24 months
about 24 months
OS ;
Tidsramme: about 48 months
about 48 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

30. oktober 2026

Primær færdiggørelse (Anslået)

30. december 2028

Studieafslutning (Anslået)

30. december 2030

Datoer for studieregistrering

Først indsendt

30. september 2026

Først indsendt, der opfyldte QC-kriterier

30. september 2026

Først opslået (Faktiske)

7. oktober 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

9. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. november 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner